Search Results - "Tremlett, Helen"

The gut microbiome in human neurological disease: A review by Tremlett, Helen, Bauer, Kylynda C., Appel‐Cresswell, Silke, Finlay, Brett B., Waubant, Emmanuelle

“…Almost half the cells and 1% of the unique genes found in our bodies are human, the rest are from microbes, predominantly bacteria, archaea, fungi, and…”
Get full text

Multiple sclerosis progression: time for a new mechanism-driven framework by Kuhlmann, Tanja, Moccia, Marcello, Coetzee, Timothy, Cohen, Jeffrey A, Correale, Jorge, Graves, Jennifer, Marrie, Ruth Ann, Montalban, Xavier, Yong, V Wee, Thompson, Alan J, Reich, Daniel S

“…Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors-relapsing-remitting, secondary progressive, and primary progressive-for…”
Get full text

New perspectives in the natural history of multiple sclerosis by TREMLETT, Helen, YINSHAN ZHAO, RIECKMANN, Peter, HUTCHINSON, Michael

“…Multiple sclerosis (MS) has entered an era of immunomodulatory drug treatment, the impact of which on long-term disease progression remains controversial. The…”
Get full text

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study by Wijnands, José Maria Andreas, Zhu, Feng, Kingwell, Elaine, Fisk, John David, Evans, Charity, Marrie, Ruth Ann, Zhao, Yinshan, Tremlett, Helen

“…ObjectiveLittle is known about disease-modifying treatments (DMTs) for multiple sclerosis (MS) and infection risk in clinical practice. We examined the…”
Get full text

A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease? by Forbes, Jessica D, Bernstein, Charles N, Tremlett, Helen, Van Domselaar, Gary, Knox, Natalie C

“…The human microbiome has received decades of attention from scientific and medical research communities. The human gastrointestinal tract is host to immense…”
Get full text

Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study by Wijnands, José M A, PhD, Kingwell, Elaine, PhD, Zhu, Feng, MSc, Zhao, Yinshan, PhD, Högg, Tanja, MSc, Stadnyk, Karen, MSc, Ekuma, Okechukwu, MSc, Lu, Xinya, PhD, Evans, Charity, PhD, Fisk, John D, PhD, Marrie, Ruth Ann, Prof, Tremlett, Helen, Prof

“…Summary Background Degenerative processes in neurodegenerative diseases can start years before clinical manifestation. We aimed to establish whether a multiple…”
Get full text

The Multiple Sclerosis Prodrome: Evidence to Action by Tremlett, Helen, Munger, Kassandra L, Makhani, Naila

“…A growing body of work points toward the existence of a clinically symptomatic prodromal phase in multiple sclerosis (MS) that might span 5-10 years or more. A…”
Get full text

Disability progression in multiple sclerosis is slower than previously reported by Tremlett, Helen, Paty, Donald, Devonshire, Virginia

“…To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception…”
Get full text

Five years before multiple sclerosis onset: Phenotyping the prodrome by Wijnands, José MA, Zhu, Feng, Kingwell, Elaine, Zhao, Yinshan, Ekuma, Okechukwu, Lu, Xinya, Evans, Charity, Fisk, John D, Marrie, Ruth Ann, Tremlett, Helen

“…Background: The multiple sclerosis (MS) prodrome is poorly characterized. Objective: To phenotype the MS prodrome via health care encounters. Methods: Using…”
Get full text

Natural history of secondary-progressive multiple sclerosis by Tremlett, Helen, Yinshan Zhao, Devonshire, Virginia

“…Objective To examine prognosis and risk factors for progression to and from secondary-progressive multiple sclerosis (SPMS). Methods Patients with definite…”
Get full text

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances by Marrie, Ruth Ann, Fisk, John D, Fitzgerald, Kathryn, Kowalec, Kaarina, Maxwell, Colleen, Rotstein, Dalia, Salter, Amber, Tremlett, Helen

“…Comorbid conditions commonly affect people with multiple sclerosis (MS). Population-based studies indicate that people with MS have an increased incidence of…”
Get full text

The natural history of primary progressive multiple sclerosis by KOCH, Marcus, KINGWELL, Elaine, RIECKMANN, Peter, TREMLETT, Helen

“…Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multiple sclerosis (MS) subtypes and is currently untreatable. A previous…”
Get full text

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator by Palace, Jacqueline, Dr, Duddy, Martin, MD, Bregenzer, Thomas, PhD, Lawton, Michael, MPhil, Zhu, Feng, MSc, Boggild, Mike, MD, Piske, Benjamin, MSc, Robertson, Neil P, Prof, Oger, Joel, DM, Tremlett, Helen, PhD, Tilling, Kate, Prof, Ben-Shlomo, Yoav, Prof, Dobson, Charles, PhD

“…Summary Background In 2002, the UK's National Institute for Clinical Excellence (NICE) concluded that interferon beta and glatiramer acetate would be cost…”
Get full text

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study by Graf, Jonas, Ng, Huah Shin, Zhu, Feng, Zhao, Yinshan, Wijnands, José M. A., Evans, Charity, Fisk, John D., Marrie, Ruth Ann, Tremlett, Helen

“…Little is known about disease-modifying drug (DMD) initiation by immigrants with multiple sclerosis (MS) in countries with universal health coverage. We…”
Get full text

Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS by Tremlett, Helen L, Oger, Joel

“…A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed beta-interferon (IFNbeta) between 1995 and 2001 was carried out…”
Get full text

Associations between the gut microbiota and host immune markers in pediatric multiple sclerosis and controls by Tremlett, Helen, Fadrosh, Douglas W, Faruqi, Ali A, Hart, Janace, Roalstad, Shelly, Graves, Jennifer, Spencer, Collin M, Lynch, Susan V, Zamvil, Scott S, Waubant, Emmanuelle

“…As little is known of association(s) between gut microbiota profiles and host immunological markers, we explored these in children with and without multiple…”
Get full text

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study by Evans, Charity, Marrie, Ruth Ann, Yao, Shenzhen, Zhu, Feng, Walld, Randy, Tremlett, Helen, Blackburn, David, Kingwell, Elaine

“…ObjectiveTo determine whether better medication adherence in multiple sclerosis (MS) might be due to specialised disease-modifying drug (DMD) support…”
Get full text

Meta-analysis identifies common gut microbiota associated with multiple sclerosis by Lin, Qingqi, Dorsett, Yair, Mirza, Ali, Tremlett, Helen, Piccio, Laura, Longbrake, Erin E, Choileain, Siobhan Ni, Hafler, David A, Cox, Laura M, Weiner, Howard L, Yamamura, Takashi, Chen, Kun, Wu, Yufeng, Zhou, Yanjiao

“…Previous studies have identified a diverse group of microbial taxa that differ between patients with multiple sclerosis (MS) and the healthy population…”
Get full text

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort by Tilling, Kate, Lawton, Michael, Robertson, Neil, Tremlett, Helen, Zhu, Feng, Harding, Katharine, Oger, Joel, Ben-Shlomo, Yoav

“…The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management…”
Get full text

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population by Ng, Huah Shin, Graf, Jonas, Zhu, Feng, Kingwell, Elaine, Aktas, Orhan, Albrecht, Philipp, Hartung, Hans-Peter, Meuth, Sven G, Evans, Charity, Fisk, John D, Marrie, Ruth Ann, Zhao, Yinshan, Tremlett, Helen

“…Evidence regarding the efficacy or effectiveness of the disease-modifying drugs (DMDs) in the older multiple sclerosis (MS) population is scarce. This has…”
Get full text